Well, these drugs, who are the most appropriate patients to receive hypometic agents? In a clinic, we investigate this agent in different settings. But where we've seen activity is in a disease called myelodysplastic syndrome, where we see this kind of silencing happening extensively, and in older patients with AML. So in myelodysplastic syndrome, there's two drugs available and approved. D-citabine and 5-azocitadine, both are active and effective in MDS, and therefore the drug were first approved in this setting. Then these drugs were investigated in acute myeloid leukemia. They found to be effective, although the authorities did not approve the drug for AML in older population. Until recently, when we had combination, well, we added something to HMA therapy, and we can talk more about them later today.
HealthTree • December 7, 2022